{"url_path":"/sec/cldx/8-k/2026-06-26/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/744218/0001104659-26-078023-index.html","accession_number":"0001104659-26-078023","cik":"0000744218","ticker":"CLDX","issuer_name":"Celldex Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/744218/0001104659-26-078023-index.html","primary_entity_key":"0000744218","primary_entity_name":"Celldex Therapeutics, Inc."},"word_count":335,"has_tables":true,"body_markdown":"**Item 5.07. Submission of Matters to a Vote of Security Holders.**\n\n \n\nOn June 25, 2026, at the Annual Meeting,\nthe stockholders voted on the four proposals listed below. The proposals are described in detail in the Company’s definitive proxy\nstatement for the Annual Meeting filed with the Securities and Exchange Commission on April 29, 2026 (the “Proxy Statement”).\nThe final results for the votes regarding each proposal are set forth below.\n\n \n\n1.    The stockholders elected\nthe following individuals to serve on the Company’s board of directors until the annual meeting of stockholders to be held in 2027.\nThe tabulation of votes with respect to the election of such directors was as follows:\n\n \n\n**Nominees**\n \n**For**\n \n \n**Against**\n \n \n**Abstain**\n \n \n**Broker Non-Votes**\n \n\nHarry H. Penner, Jr. (Chair of the Board)\n \n \n59,455,265\n \n \n \n1,047,261\n \n \n \n181,190\n \n \n \n4,402,319\n \n\nAnthony S. Marucci (Chief Executive Officer)\n \n \n60,218,830\n \n \n \n282,968\n \n \n \n181,918\n \n \n \n4,402,319\n \n\nKeith L. Brownlie\n \n \n59,858,683\n \n \n \n644,110\n \n \n \n180,923\n \n \n \n4,402,319\n \n\nCheryl L. Cohen\n \n \n60,046,578\n \n \n \n456,194\n \n \n \n180,944\n \n \n \n4,402,319\n \n\nHerbert J. Conrad\n \n \n59,524,978\n \n \n \n975,608\n \n \n \n183,130\n \n \n \n4,402,319\n \n\nRita I. Jain, M.D.\n \n \n59,495,870\n \n \n \n1,000,240\n \n \n \n187,606\n \n \n \n4,402,319\n \n\nJames J. Marino\n \n \n59,910,902\n \n \n \n591,402\n \n \n \n181,412\n \n \n \n4,402,319\n \n\nGarry A. Neil, M.D.\n \n \n59,570,030\n \n \n \n932,772\n \n \n \n180,914\n \n \n \n4,402,319\n \n\nDenice Torres\n \n \n60,135,775\n \n \n \n366,304\n \n \n \n181,637\n \n \n \n4,402,319\n \n\n \n\n2.    The stockholders approved\nthe ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm\nfor the year ending December 31, 2026. The tabulation of votes with respect to this proposal was as follows:\n\n \n\n**For**\n \n**Against**\n \n**Abstain**\n\n64,712,039\n \n174,706\n \n199,290\n\n \n\n3.    The stockholders approved\nan amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of the shares reserved for issuance thereunder\nby 3,400,000 shares to 12,900,000 shares. The tabulation of votes with respect to this proposal was as follows:\n\n \n\n**For**\n \n**Against**\n \n**Abstain**\n \n**Broker Non-Votes**\n\n58,844,414\n \n1,654,297\n \n185,005\n \n4,402,319\n\n \n\n4.     The stockholders voted\nto approve, on an advisory, non-binding basis, the compensation for the Company’s named executive officers as disclosed in the Proxy\nStatement. The tabulation of votes with respect to this proposal was as follows:\n\n \n\n**For**\n \n**Against**\n \n**Abstain**\n \n**Broker Non-Votes**\n\n59,258,619\n \n945,414\n \n479,683\n \n4,402,319\n\n \n\n-2-"}